Quintrio
Home

Stock overview

Ascentage Pharma Group International American Depository Shares

AAPG

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $13.13 – $13.52
Volume 2,215
Market cap $1.24B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for AAPG.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for AAPG.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

Ascentage Pharma announced that lisaftoclax has been included in China's 2026 National Reimbursement Drug List (NRDL) for treating chronic lymphocytic leukemia/small lymphocytic lymphoma, while olverembatinib successfully renewed its NRDL coverage for chronic myeloid leukemia treatment. Both approvals take effect January 1, 2027, and represent all approved indications for both drugs now being covered by the NRDL, significantly improving patient access and affordability in China.

GlobeNewswire Inc.

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

Ascentage Pharma announced that its novel Bcl-2 inhibitor lisaftoclax (APG-2575) has received Breakthrough Therapy Designation (BTD) from China's NMPA in combination with acalabrutinib for treating treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The BTD designation accelerates development and review processes, potentially enabling priority review and conditional approval pathways. Lisaftoclax was previously approved in China in July 2025 for relapsed/refractory CLL/SLL patients.

GlobeNewswire Inc.

Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer

Ascentage Pharma announced the appointment of Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer to strengthen global business development and US commercialization efforts. Both executives bring extensive experience in oncology and specialty therapeutics, with the company advancing multiple Phase III registrational studies for its pipeline of cancer therapies.

GlobeNewswire Inc.

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.

GlobeNewswire Inc.

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Ascentage Pharma announced seventeen clinical updates from its core assets at the 31st European Hematology Association Congress, including eight poster presentations. Key data showed olverembatinib demonstrated deep and durable responses in chronic myeloid leukemia (CML) patients resistant to first-line therapy and robust clinical response in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Lisaftoclax showed promising efficacy in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and myeloid neoplasms, with a chemotherapy-free combination regimen yielding encouraging results in pediatric patients with relapsed/refractory Ph+ ALL.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 7, 20033-for-1forward split